On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The successful human papillomavirus (HPV) and hepatitis B virus (HBV) subunit vaccines contain single viral proteins that represent 22% and 12%, respectively, of the total antigens encoded by these simple viruses. The herpes simplex virus 2 (HSV-2) genome is 20 and 50 times larger, respectively. Thus, single protein subunit vaccines represent only 1% of HSV-2’s total antigenic breadth. The concept of antigenic breadth offers a unifying explanation for why HSV-2 glycoprotein D subunit vaccines have repeatedly failed in human clinical trials, and why live HSV-2 vaccines that encode 99% of HSV-2’s antigens are more effective in side-by-side tests. We believe that live HSV-2 vaccines represent an unexplored opportunity to stop the genital herpes epidemic.
